dc.contributor.author | Kalyoncu, Umut | |
dc.contributor.author | Kiraz, Sedat | |
dc.contributor.author | Apras Bilgen, Sule | |
dc.contributor.author | Karadağ, Ömer | |
dc.contributor.author | Akdoğan, Ali | |
dc.contributor.author | Kılıç, Levent | |
dc.contributor.author | Erden, Abdulsamet | |
dc.contributor.author | Armagan, Berkan | |
dc.contributor.author | Sari, Alper | |
dc.contributor.author | Ertenli, İhsan | |
dc.date.accessioned | 2021-03-17T07:47:40Z | |
dc.date.available | 2021-03-17T07:47:40Z | |
dc.date.issued | 2019-01-21 | |
dc.identifier.citation | Kalyoncu U, Kiraz S, Bilgen SA, Karadag O, Akdogan A, Kilic L, Erden A, Armagan B, Sari A, Ertenli I. Change in PsAID-12 scores in patients continuing or discontinuing anti-TNF treatments in psoriatic arthritis: results from the HUR-BIO biologic registry. Clin Rheumatol. 2019 Apr;38(4):1187-1192. doi: 10.1007/s10067-019-04426-3. Epub 2019 Jan 21. PMID: 30663017. | tr_TR |
dc.identifier.issn | 0770-3198/ 1434-9949 | |
dc.identifier.uri | http://hdl.handle.net/11655/23566 | |
dc.identifier.uri | https://doi.org/10.1007/s10067-019-04426-3 | |
dc.identifier.uri | https://pubmed.ncbi.nlm.nih.gov/30663017/ | |
dc.description.abstract | Objective
Psoriatic Arthritis Impact of Disease 12-item questionnaire (PsAID-12) has been developed to be used in psoriatic arthritis in daily practice. The aim of the present study was to assess the change values of PsAID-12 in PsA patients continuing or discontinuing anti-TNF treatment.
Methods
We recruited patients from the Hacettepe University biological database (HUR-BIO). Overall, 70 PsA patients had PsAID-12 score before the initiation of the first anti-TNF treatment. Stopping or switching the anti-TNF treatment due to inefficacy was definitely considered a negative response. Changes were evaluated by the comparison with the baseline PsAID-12 score in compliance with the favorable and unfavorable responses to anti-TNF treatments. The standardized response mean (SRM) was used for determining the response.
Results
Seventy (78.6% female) patients were analyzed and their mean age was 45.5 years (12.0 years). The mean follow-up duration was 18.3 months (12.6 months). At baseline, the mean PsAID-12 score was 6.6 (1.5). Physicians stopped or switched the treatment in 28 patients (40.0%) due to the inefficacy of anti-TNF treatment. The ΔPsAID-12 score was 0.25 (1.71) in the patients discontinuing anti-TNF treatment and 3.52 (2.31) in the patients continuing their anti-TNF treatment (p < 0.001). The SRM scores higher for PsAID-12, particularly in the well response to anti-TNF treatments.
Conclusion
A decrease of 3.5 units in PsAID-12 score shows a favorable response to anti-TNF treatment. Changes in PsAID-12 score had well discrimination capacity for anti-TNF treatments. | tr_TR |
dc.language.iso | en | tr_TR |
dc.publisher | Springer | tr_TR |
dc.relation.isversionof | 10.1007/s10067-019-04426-3 | tr_TR |
dc.rights | info:eu-repo/semantics/openAccess | tr_TR |
dc.rights.uri | http://creativecommons.org/publicdomain/zero/1.0/ | * |
dc.subject | Psoriatic Arthritis | tr_TR |
dc.subject | Anti-TNF treatment | tr_TR |
dc.subject.lcsh | Tıp uygulaması | tr_TR |
dc.title | Change in PsAID-12 scores in patients continuing or discontinuing anti-TNF treatments in psoriatic arthritis: results from the HUR-BIO biologic registry | tr_TR |
dc.type | info:eu-repo/semantics/article | tr_TR |
dc.type | info:eu-repo/semantics/publishedVersion | |
dc.relation.journal | Clinical Rheumatology | tr_TR |
dc.contributor.department | İç Hastalıkları | tr_TR |
dc.identifier.volume | 38 | tr_TR |
dc.identifier.startpage | 1187 | tr_TR |
dc.identifier.endpage | 1192 | tr_TR |
dc.description.index | PubMed | tr_TR |
dc.funding | Yok | tr_TR |